Securities Star News, on October 24, 2024, Cain Technology (688687) announced that the company will accept institutional research on October 22, 2024, Guosheng Securities, Soochow Securities, Beijing Oriental Ruishi Investment Management Co., Ltd., Bank of China Asset Management, Bohai Life Insurance Co., Ltd., Jingxi Investment, Ping An Securities, Chinese Insurance Asset Management Co., Ltd., Shanghai Gaoyi Asset Management Partnership (Limited Partnership), Shanghai Natural Shibei Investment Management Partnership (Limited Partnership), Everbright Securities Co., Ltd., Fuanda Fund Management Co., Ltd., Western Securities, Chang'an Fund Management Co., Ltd., Liuren Assets, Tianzhi Fund Management Co., Ltd., ABC Huili Fund Management Co., Ltd., Beijing Hongcheng Investment Management Co., Ltd., Taixin Fund Management Co., Ltd., Endowment Capital, Cindat Life Insurance, China Post Venture Fund Management Co., Ltd., China Securities Construction Investment Fund Management Co., Ltd., Guohai Securities, E Fund Management Co., Ltd., Guangzhou Jinxin Private Equity, Ruizhi Capital, China Merchants Cigna Asset Management Co., Ltd., Huaan Fund, Founder Securities, Everbright Sun Life Asset Management Co., Ltd., Chongyun Investment, China Merchants Fund Management Co., Ltd., Shanghai Shengmeng Asset Management Co., Ltd., Huatai Securities, Galaxy Securities, Sunshine Capital, Alluvial Assets, Kaiyuan Securities, Anhua Agricultural Insurance Co., Ltd., Huaxin Securities, Ningyin Wealth Management Co., Ltd., Beijing Jinbairong Investment, Qingrong Asset Management Co., Ltd., Caixin Securities Co., Ltd., Guosen Securities, Essence Fund, Hunan Pharmaceutical Development Fund, Shanghai Yinbei Investment Management Co., Ltd., Ruiyuan Fund Management Co., Ltd., Yuanxin Investment, Zheshang Fund, Zheshang Securities, Chenhe Investment, Southwest Securities, Industrial Securities, Yongying Fund Management Co., Ltd., Hua United States International Investment Group Co., Ltd., Huaxi Fund Management Co., Ltd., Debang Securities, Jinglin Assets, Shanghai Guotai Junan Securities Asset Management Co., Ltd., Shanghai Danyi Investment Management Partnership (General Partnership), Shanghai Qushi Asset Management Co., Ltd., Bianyu, Everbright Prudential Fund Management Co., Ltd., Hehe (Beijing) Private Equity Fund Management Co., Ltd., Convergence Capital Management Co., Ltd., Guangdong Zhengyuan Private Equity Fund Management Co., Ltd., Superstring Capital, Shenwan Hongyuan, Essence Fund Management Co., Ltd., Dacheng Fund Management Co., Ltd., Jinlin Investment, CITIC Securities Co., Ltd., Guangzhou Xuanjia Private Equity Fund Management Co., Ltd., Guotai Fund, Shenzhen Shangcheng Assets, Shanghai Fenglan Asset Management Co., Ltd., ABC Life Insurance Co., Ltd., Guosen Securities Co., Ltd., CITIC Securities, Youyi Zeng Investment, Huaneng Guicheng Trust Co., Ltd., Shanghai Mengyang Investment Management Co., Ltd., Hang Seng Qianhai Fund Management Co., Ltd., Shandong High-speed Co., Ltd., Shenzhen Yihu Investment Management Co., Ltd., AIA, Harvest Fund Management Co., Ltd., Pinpoint, Hangzhou Huisheng Investment Management Co., Ltd., Minsheng Securities, Rongtong Fund Management Co., Ltd., Shanghai Jiupeng Asset Management Center (Limited Partnership). ), Tianworm Capital, AVIC Fund, Shanghai Xishirun Investment Management Co., Ltd., Penghua Fund Management Co., Ltd., Chengshi Investment, Shanghai Licheng Asset Management Co., Ltd., Cinda Australasia Fund Management Co., Ltd., China Wealth, Guojin Securities, Harbour Life Insurance, Hongta Laterite Fund Management Co., Ltd., Windsor Capital, Shenzhen Ruiquan Yixin Investment Management Co., Ltd., Jinxin Fund Management Co., Ltd., Shenwan Lingxin, Huatai Proprietary Management, Guohai Securities Asset Management, Pengyang Fund Management Co., Ltd., Changsheng Fund Management Co., Ltd., Huaxi Securities, Mingyu Assets, China Post Securities Co., Ltd., Zheshang Self-operated, China Merchants Securities Asset Management Co., Ltd., Hengyue Fund Management Co., Ltd., Red Chip Investment, Huachuang Securities Co., Ltd., Point72 Hong Kong Limited, Shenzhen Jingtai Lifeng Investment Development Co., Ltd., BOC International Securities Co., Ltd., Haitong Securities, Chuangjin Hexin Fund Management Co., Ltd., Guorong Securities, Beijing Zundao Asset Management Co., Ltd., Zhonggeng Fund Management Co., Ltd, Guodu Asset Management, Zhongrong Huixin Investment Co., Ltd., Jingyan Private Equity, Donghai Fund Management Co., Ltd., Shanghai Ruiyi Investment Development Center (Limited Partnership), Orient Securities Co., Ltd., Capital Securities, Huiquan Fund Management Co., Ltd., Founder Asset Management Equity Investment Department, Hangzhou Bank Wealth Management Co., Ltd., Jinyuan Shun'an Fund Management Co., Ltd., Shanghai Ice Asset Management Co., Ltd., Orient Securities Derivatives, Wells Fargo Fund, Shanghai Tongyuan Investment Development Co., Ltd., Invesco Great Wall Fund Management Co., Ltd., Templeton Investment Advisors Limited participated.

The details are as follows:

Q: What is the latest progress of the company's long-acting interferon declaration?

A: The marketing authorization application of the company's interferon-α-2 injection to increase the new indication of chronic hepatitis B in adults has been accepted by the State Food and Drug Administration, and please pay attention to the company's announcement for follow-up progress. Thank you!

2. What is the reason for the decrease in the sales expense ratio in the third quarter?

The main reason is that the company's interferon centralized procurement products have decreased in most provinces in the third quarter, and the company's continuous promotion of cost reduction and efficiency improvement measures has gradually achieved results. Thank you!

3. What is the reason for the company's acquisition of the minority shareholders' shares?

After the completion of the acquisition, the company will hold 81% of the equity of Kaiingeling, which is conducive to enhancing the company's control and decision-making efficiency of the subsidiary, realizing the effective allocation of the company's overall resources, and conforming to the long-term development plan of the company and its subsidiaries. Thank you!

4, Jin Shuxi? What is the current implementation of centralized procurement?

As of the end of September, more than 90% of Jin Shuxi? The implementation of centralized procurement has begun in the provinces. Thank you!

5. Can you give a detailed introduction to Derivation? What are the product benefits?

Interferon α-2 Injection (trade name derived from Yisheng?) is an antiviral drug with independent intellectual property rights of the company, which is a therapeutic biological product with a new drug certificate. Interferon α-2 injection is a recombinant integrated interferon modified by PEG, in which recombinant integrated interferon is obtained by sequence homology comparison of more than 10 natural α-interferon isoforms, following the highest principle of homologous sequence, the activity is higher than that of general α type interferon, the half-life is long, suitable for once-a-week administration, with good convenience, it has both antiviral and immunomodulatory effects, and is one of the drugs that pursue clinical cure of chronic viral hepatitis B. Derivation? In addition to the new indication for hepatitis B, clinical trials are also being carried out for the treatment of herpes zoster and the treatment of hepatic epithelioid hemangioendothelioma. Thank you!

6. What are the company's main research projects? What is the expected level of R&D investment in the future?

At present, the company focuses on the research and development of hepatitis B functional cure drug combination with innovative drugs as the core, and has laid out a product pipeline covering various drug types such as recombinant proteins, monoclonal antibodies, siRNs, etc., focusing on various mechanisms such as antiviral, hepatitis B surface antigen inhibition, and immune regulation. The company will invest sufficient resources to ensure the company's R&D progress and the realization of R&D goals after comprehensive consideration of various factors. Thank you!

Cain Technology (688687) main business: a high-tech biopharmaceutical company focusing on the field of viruses and immune diseases, integrating R&D, production and sales of innovative drugs.

According to the third quarter report of Kain Technology in 2024, the company's main revenue was 1.011 billion yuan, an increase of 0.82% year-on-year; the net profit attributable to the parent company was 108 million yuan, an increase of 19.74% year-on-year; deducted non-net profit of 110 million yuan, an increase of 16.26% year-on-year; In the third quarter of 2024, the company's single-quarter main revenue was 414 million yuan, a year-on-year decrease of 4.51%; The net profit attributable to the parent company in a single quarter was 65.6642 million yuan, an increase of 26.53% year-on-year; The non-net profit deducted in a single quarter was 65.5809 million yuan, an increase of 23.69% year-on-year; The debt ratio was 29.1%, the investment income was 318,200 yuan, the financial expenses were -11,645,900 yuan, and the gross profit margin was 81.94%.

A total of 10 institutions have rated the stock in the last 90 days, 7 have given buy ratings and 3 have overweight ratings. The average institutional price target over the last 90 days is 44.13.

Here's the detailed earnings forecast information:

Margin data shows that the stock has a net financing outflow of 8.7995 million in the past three months, with a decrease in the financing balance, and a net outflow of 179,000 with a decrease in the balance of securities borrowing and lending.

The above content is compiled by Securities Star based on public information, generated by intelligent algorithms, and does not constitute investment advice.